A Randomized Phase II Study of Radiotherapy Plus Immune Checkpoint Inhibitor Therapy Versus Standard of Care Chemotherapy in Patients With Metastatic or Relapsed Non-Small Cell Lung Cancer Previously Treated With Immunotherapy
University of Chicago
Summary
Current clinical trials testing the combination of immunotherapy with radiotherapy.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Disease-Related Criteria * Patients must have histologically or cytologically confirmed metastatic or recurrent non-small cell lung cancer (NSCLC) with progression on prior immunotherapy * The patient's disease is eligible for SOC treatment with immunotherapy or chemotherapy. * Patients must have measurable disease per RECIST v1.1, defined as at least one lesion that can be accurately measured in at least one dimension with longest diameter ≥10 mm (or ≥15 mm short axis for lymph nodes) by CT or MRI * Patients must have at least one lesion that meets criteria for…
Interventions
- DrugInvestigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab)
Participant will receive an FDA approved immunotherapy according to usual routine practice.
- DrugInvestigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments)
Description something along the lines of Participant will receive an FDA approved chemotherapy according to usual routine practice.
- RadiationAblative Hypofractionated Radiotherapy
Participant will receive radiotherapy according to usual routine practice.
Location
- o University of Chicago Medicine Comprehensive Cancer CenterChicago, Illinois